Navigation Links
Study explores the role of uncertainty in infectious disease modelling
Date:10/21/2013

Research by scientists at the University of Liverpool has found that greater consideration of the limitations and uncertainties present in every infectious disease model would improve its effectiveness/usefulness and value.

Infectious disease dynamical modelling plays a central role in planning for outbreaks of human and livestock diseases, in projecting how they might progress and guiding and informing policy responses.

Modelling is commissioned by governments or may be developed independently by researchers. It has been used to inform policy decisions for human and animal diseases such as SARS, H1N1 swine influenza, foot-and-mouth disease and is being used to inform action in the campaign to control bovine TB.

In a study published in PLOS One, researchers analysed scientific papers, interviews, policies, reports and outcomes of previous infectious diseases outbreaks in the UK to ascertain the role uncertainties played in previous models and how these were understood by both the designers of the model and the users of the model.

They found that many models used to respond to epidemics provided only cursory reference to the uncertainties of the information and data or the parameters used. Whilst the models were uncertain many still informed action.

Dr Rob Christley, from the University's Institute of Infection and Global Health, said: "It is accepted that models will never be able to predict 100% the size, shape or form of an outbreak and it is recognised that a level of uncertainty always exists in modelling. However, modellers often fear detailed discussion of this uncertainty will undermine the model in the eyes of policy makers.

"This study found that the uncertainties and limitations of a model are sometimes hidden and sometimes revealed, and that which occurs is context dependent.

"Whilst it isn't possible to calculate the level of uncertainty, a better understanding and communication of the model's limitations is needed and could lead to better policy."

A model is produced by individuals who have to decide what is important and need to bring together data and information which could include population data, age of population, proximity, type of disease. Uncertainty can occur at all stages of the process from weaknesses in the quality and type of data used, assumptions made about the infectious agent itself, and about the world in which the disease is circulating, all the way through to the technical aspects of the model.


'/>"/>

Contact: Sarah Stamper
sarah.stamper@liv.ac.uk
01-517-943-044
University of Liverpool
Source:Eurekalert

Related biology news :

1. Clean living is a luxury wild animals cant afford, study suggests
2. Study puts freshwater biodiversity on the map for planners and policymakers
3. What makes us left or right handed? New study rules out strong genetic factors
4. Study: Acidity can change cell membrane properties
5. Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication
6. $1.5 million NCI Grant to aid Huntsman Cancer Institute researcher study melanoma, sun damage link
7. Study finds steroids may persist longer in the environment than expected
8. New study offers hope for halting incurable citrus disease
9. Global study reveals new hotspots of fish biodiversity
10. Family Resiliency Center helps study how food-bank clients afford basic non-food items
11. New CU-Boulder-led study finds microbial clock may help determine time of death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... -- According to a new market research report "Emotion Detection and ... Recognition), Service, Application Area, End User, And Region - Global Forecast to 2021", ... Billion in 2016 to USD 36.07 Billion by 2021, at a Compound Annual ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 7, 2016   Avanade is helping Williams ... teams in history, exploit biometric data in order to ... maintain the competitive edge against their rivals after their ... Avanade has worked with Williams during the 2016 ... data (heart rate, breathing rate, temperature and peak acceleration) ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, a ... heart failure and type 2 diabetes, announced that ... novel adeno-associated virus (AAV) vector developed in the ... Ph.D., at Stanford University. The company plans to ... gene therapy product pipeline. "Early ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard ...
(Date:12/8/2016)... 2016  Anaconda BioMed S.L., a pre-clinical stage medical ... generation neuro-thrombectomy system for the treatment of Acute Ischemic ... MD to join its Scientific Advisory Board (SAB). The ... of scientific and clinical experts to Anaconda BioMed S.L., ... BRAIN ® to its clinical phase. The SAB ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, ... uBiome is one of just six company finalists in the Health & Medicine ... uBiome, companies nominated as finalists in this year’s awards include Google, SpaceX, Oculus, ...
Breaking Biology Technology: